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Introduction: The reprogramming of a patient’s somatic cells back into induced pluripotent stem cells (iPSCs)
holds significant promise for future autologous cellular therapeutics. The continued presence of potentially
oncogenic transgenic elements following reprogramming, however, represents a safety concern that should be
addressed prior to clinical applications. The polycistronic stem cell cassette (STEMCCA), an excisable lentiviral
reprogramming vector, provides, in our hands, the most consistent reprogramming approach that addresses this
safety concern. Nevertheless, most viral integrations occur in genes, and exactly how the integration, epigenetic
reprogramming, and excision of the STEMCCA reprogramming vector influences those genes and whether these
cells still have clinical potential are not yet known.
Methods: In this study, we used both microarray and sensitive real-time PCR to investigate gene expression
changes following both intron-based reprogramming and excision of the STEMCCA cassette during the generation
of human iPSCs from adult human dermal fibroblasts. Integration site analysis was conducted using nonrestrictive
linear amplification PCR. Transgene-free iPSCs were fully characterized via immunocytochemistry, karyotyping and
teratoma formation, and current protocols were implemented for guided differentiation. We also utilized current
good manufacturing practice guidelines and manufacturing facilities for conversion of our iPSCs into putative
clinical grade conditions.
Results: We found that a STEMCCA-derived iPSC line that contains a single integration, found to be located in an
intronic location in an actively transcribed gene, PRPF39, displays significantly increased expression when compared
with post-excised stem cells. STEMCCA excision via Cre recombinase returned basal expression levels of PRPF39.
These cells were also shown to have proper splicing patterns and PRPF39 gene sequences. We also fully
characterized the post-excision iPSCs, differentiated them into multiple clinically relevant cell types (including
oligodendrocytes, hepatocytes, and cardiomyocytes), and converted them to putative clinical-grade conditions
using the same approach previously approved by the US Food and Drug Administration for the conversion of
human embryonic stem cells from research-grade to clinical-grade status.
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Conclusion: For the first time, these studies provide a proof-of-principle for the generation of fully characterized
transgene-free human iPSCs and, in light of the limited availability of current good manufacturing practice cellular
manufacturing facilities, highlight an attractive potential mechanism for converting research-grade cell lines into
putatively clinical-grade biologics for personalized cellular therapeutics.Introduction
Previous research demonstrated that human somatic cells
can be directly reprogrammed back into an induced pluri-
potent stem cell (iPSC) state through exogenous expres-
sion of a small number of transgenic factors [1]. The
ability of these cells to differentiate into any human cell
type highlights their promise for future autologous cellular
therapies [2,3]. Nevertheless, the continued presence of
potentially oncogenic transgenic elements following re-
programming represents a safety concern that must be
addressed prior to clinical applications [4-7]. Various
integration-free approaches have been investigated to ad-
dress this safety concern. Of the various techniques tested
to date – that is, episomal plasmids [8], minicircles [9],
nonintegrating miRNAs [10,11], cell-permeable proteins
[12], sendai viruses [13], synthetic mRNAs [14] and the
removable polycistronic stem cell cassette (STEMCCA) –
and despite each having published reprogramming success
(Table 1), only the STEMCCA-based reprogramming ap-
proach, in our hands, has consistently and successfully re-
programmed dermal fibroblasts from multiple different
adult donors into iPSCs.
Advantages of the STEMCCA reprogramming ap-
proach include the following: lentiviruses can transduce
both dividing and nondividing cells; the STEMCCA
polycistronic cassette was engineered for efficient pro-
duction of multiple protein products from a single len-
tivirus and allows a characteristic stoichiometry of
protein expression that reproducibly promotes consist-
ent reprogramming success [15,19]; the STEMCCA ap-
proach involves only a single transduction event,
making it less labor intensive than more involved repro-
gramming methods such as synthetic mRNAs; the
STEMCCA cassette is excisable, eliminating residual
transgene expression that reportedly compromises dif-
ferentiation potential [20]; and iPSCs can be generated
to contain only one integration event and accurately




Efficiency (%) 0.022 0.01 to 1.5 <0.01 to 0.02 0.003 to 0.0
Integrating Yes Yes Yes No
Reference(s) [1] [15,16] [17,18] [8,9]cell types have been reprogrammed through polycis-
tronic lentivirus-mediated reprogramming, including
human keratinocytes, bone marrow cells, skin fibro-
blasts [22], and T cells from peripheral blood [23] and
also from patients with diseases such as Huntington’s
disease [24], heart failure [25], immunodeficiency disor-
ders [26], lung disease [16], and neurodevelopmental
disorders [27]. Nevertheless, the majority (approxi-
mately 70%) of lentiviral integrations occur in actively
transcribed genes [28,29]. Because current safe-harbor
criteria discard iPSC lines that result from a viral inte-
gration occurring in a gene [30], this greatly reduces the
feasibility of STEMCCA-iPSC-based therapeutics. We
and others have previously relied solely on microarray
transcriptional analysis to assess the expression of genes
following insertion of STEMCCA into the introns of
genes [30,31].
In this study, we use both microarray and sensitive
real-time RT-PCR to investigate gene expression changes
following both intron-based integration and excision of
the STEMCCA cassette during the generation of human
induced pluripotent stem cells (hiPSCs). We also fully
characterized the post-excised iPSCs, differentiated them
into four therapeutically useful cell types, and converted
them into putative clinical-grade conditions.
Materials and methods
Ethics statement
Written approvals for human skin biopsy procedures
and human fibroblast derivation, culture, and experi-
mental use were obtained from the Stanford University
Institutional Review Board (Stanford IRB protocol
#10368) and the Stanford University Stem Cell Research
Oversight Committee (Stanford SCRO protocol #40),
and written informed consent was obtained from each
individual participant. Cells used in this study were
initially derived at Stanford University and transferred
to UCLA through a material transfer agreement (UCLAefficiencies from human dermal fibroblasts
minicircle miRNAs Cell-permeable proteins Sendai virus mRNA
06 0.002 0.001 0.01 to 1 >1
No No No No
[11] [12] [13] [14]
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periments performed in this study were obtained from
the UCLA Institute Biosafety Committee (UCLA IBC
protocol #123.10.0-f ), the Animal Research Committee
(UCLA ARC protocol #2006-119-21) and the Stem Cell
Research Oversight Committee (UCLA SCRO protocol
#2010-010-02).
In vitro culture of primary human skin cells
The human skin-derived (HUF1) primary cell line used in
this study was obtained from a 4-mm adult skin punch bi-
opsy and was cultured as described [32]. Two other fibro-
blast lines were also used in this study: an infant fibroblast
line (MGM2) and a fibroblast line from Fibrocell Science,
Inc. (Exton, PA, USA) (azficel-T (LAVIV) part #DR01/
RMS-5519v00). All human biopsy-derived cells and fibro-
blast lines were cultured in complete DMEM/F-12 media
consisting of DMEM nutrient mixture/F-12 supplemented
with 10% fetal bovine serum (FBS), 1× minimum essential
medium nonessential amino acid, 1× Glutamax, and 100
IU/ml penicillin–streptomycin (all from Invitrogen/Gibco,
Grand Island, NY, USA) and maintained at 37°C in a 5%
CO2 incubator. Culture media were changed every 2 days.
Cells were allowed to expand to 80 to 90% confluency be-
fore passaging with 0.05% trypsin–ethylenediamine
tetraacetic acid (Invitrogen) and replating at a 1:3 ratio. A
large bank of early-passage HUF1 cells was cryopreserved
in culture media supplemented with 10% dimethyl sulfox-
ide (Sigma-Aldrich, St Louis, MO, USA). All research ad-
hered to National Academy of Sciences guidelines.
In vitro culture of stem cell lines
Human-1, human-2, and human-9 embryonic stem cell
(ESC) lines were provided by the UCLA Broad Stem Cell
Research Center-Stem Cell Core. Multiple integration
iPSCs were derived as previously published [31]. The
mRNA hiPSCs were derived using Stemgent’s mRNA
reprogramming factor set (Stemgent, San Diego, CA,
USA). The adult pre-excision line (termed C-8, or pre-
excised iPSC) and the adult post-excision line (termed
2.3, or post-excised iPSC), derived as explained below,
were all initially maintained on 0.2% gelatin-coated six-
well plates covered with 35,000 cells/cm2 irradiated mouse
embryonic fibroblasts (MEFs) (GlobalStem, Rockville,
MD, USA) with standard ESC media consisting of
DMEM/F-12 supplemented with 20% Knockout Serum
Replacement, 1× Glutamax, 1× nonessential amino acid,
100 IU/ml penicillin–streptomycin (all from Invitrogen),
1× β-mercaptoethanol (Millipore, Billerica, MA, USA),
and 10 ng/ml recombinant human basic fibroblast
growth factor (Globalstem). All cells were transitioned
into a feeder-free system and subsequently maintained
on reduced growth factor Matrigel (BD Biosciences,
San Jose, CA, USA) in mTeSR1 medium (Stem CellTechnologies, Vancouver, BC, Canada) supplemented with
10 ng/ml basic fibroblast growth factor (Globalstem) and
1× Primocin (InvivoGen, San Diego, CA, USA). Media
were changed daily. Cells were passaged every 4 to 5
days, depending on colony density and size. Differenti-
ation was removed daily from colonies using pulled
glass pipettes. To passage the pluripotent stem cells, an
18-gauge needle was used to cross-hatch colonies in a
grid format, with subsequent gentle agitation to remove
the pieces with a P200 pipette. Usually, 4 to 8 colonies
were passaged onto freshly coated Matrigel plates.
Lentivirus production and infection
For pre-excised and post-excised iPSC lines, lentiviral hu-
man STEMCCA vector was synthesized and packaged as
published [15] and was concentrated to 100×. The day be-
fore infection, 100,000 cells/well were plated in a six-well
plate grown in standard DMEM/F-12 media without anti-
biotics. On the day of transduction, 100× lentiviral super-
natant was thawed, and 2 ml MEF conditioned media
from each well of fibroblasts to be infected was taken out
and mixed with 2× and 4× viral supernatant concentra-
tions, respectively, with 8 μg/ml polybrene (Millipore).
This virus-containing mixture was quickly added to the
cells to avoid drying, shaken gently, and placed at 37°C in
a 5% CO2 incubator overnight. From day 2 through day 6,
media were changed every day with DMEM/F-12 medium
with antibiotics. Irradiated xCF1 fibroblasts harvested
from day 8 mouse embryos were plated on day 6, and
50,000 and 100,000 cells from one well in a six-well plate
were plated on day 7 onto an MEF-plated 10-cm plate and
left to sit at 37°C in a 5% CO2 incubator overnight. The
next day, MEF media were replaced with human ESC
medium for the duration of the reprogramming and
changed daily. Colonies were picked on the parental plate
when colonies reached the size of 60 to 70% of 5× field
view or became three-dimensional/differentiated into cell
aggregates. Each parental colony was cut into two or three
pieces and seeded onto a 24-well plate preseeded with
xCF1 mouse feeders, one clone per well. Colonies were
grown and further subcloned out according to optimal
growth and colony morphology (flattened, very little dif-
ferentiation, and high nucleus-to-cytoplasm ratio) and
when colonies reached 60 to 70% of 5× field. Subcloning
into a 12-well plate required 8 to 10 pieces from each
clone per well from a 24-well plate be placed into an xCF1
MEF precoated 12-well plate. The pieces were then even-
tually subcloned out to a six-well plate for further
characterization.
Vector integration site analysis by nonrestrictive linear
amplification PCR
DNA was isolated from iPSCs using the PureLink
Genomic DNA Mini Kit (Invitrogen). Approximately
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tive linear amplification (nrLAM) PCR [33]. Briefly,
100 cycles of linear amplification were performed with
primer HIV3linear (Biotin-agtagtgtgtgcccgtctgt). Linear re-
actions were purified using 1.5 volumes of AMPure XP
beads (Beckman Genomics, Indianapolis, IN, USA) and
captured onto 100 μg of M-280 Streptavidin Dynabeads
(Invitrogen Dynal), prepared in accordance with the in-
structions of the manufacturer. Captured ssDNA was
ligated to read 2 linker (Phos-agatcggaagagcacacgtctgaa
ctccagtcac-3C Spacer) using CircLigase II (Epicentre,
Madison, WI, USA) in a 10 μl reaction at 65° for 2 hours.
PCR was performed on these beads using primer HIV3right
(aatgatacggcgaccaccgagatctacactgatccctcagacccttttagtc) and
an appropriate indexed reverse primer (caagcagaagacgg
catacgagat-index-gtgactggagttcagacgtgt). PCR products
were mixed and quantified by probe-based quantitative
PCR, and appropriate amounts were used to load
Illumina v3 flow cells (Illumina, San Diego, CA, USA).
Paired-end 50-base-pair sequencing was performed on an
Illumina HiSeq 2000 instrument using a custom read 1 pri-
mer (ccctcagacccttttagtcagtgtggaaaatctctagca). Reads were
aligned to the hg19 build of the human genome with
Bowtie [34], and alignments were condensed and annotated
using custom Perl and Python scripts to locate vector
integrations.
Infection of induced pluripotent stem cells with adeno-Cre
Excision of STEMCCA was performed by transient
transduction of a defective adenoviral vector expressing
Cre-recombinase-puromycin (Adeno-Cre-puroR), which
was generated by Vector BioLabs (Philadelphia, PA,
USA) to express Cre recombinase and puromycin resist-
ance, into the parental pre-excised iPSC line. We used
45 and 5 μl concentrated Adeno-Cre-puroR virus with 8
μg/ml polybrene (Millipore) in standard ESC media for
24 hours. After 24 hours (on day 1), the mixed viral
supernatant was removed, and the cells were washed
twice with ESC media and then cultured in fresh ESC
media containing 2 μg/ml puromycin (Invitrogen) for a
period of 5 days. Individual colonies still growing after 5
days were subcloned into 12-well plates and expanded
as described above.
Genomic and RT-PCR analysis
Genomic DNA was isolated from pluripotent stem cells
(PSCs) grown in feeder-free conditions with the
PureLink Genomic DNA Mini Kit (Invitrogen) in ac-
cordance with the instructions of the manufacturer. PCR
was performed using the KAPA HiFi Hotstart ReadyMix
PCR kit (KAPA, Woburn, MA, USA) with a five-step
PCR protocol as follows: initial denaturation at 95°C for
3 minutes; 35 cycles of each of the following: denaturation
at 98°C for 20 seconds, primer annealing at 62°C for 15seconds, and extension at 72°C for 15 seconds; followed
by a single cycle final extension at 72°C for 3 minutes. Ten
nanograms of template DNA were used. Primers specific
for exogenous integrations of the STEMCCA lentivirus
are listed as follows: gDNA-hendo-MycS-forward, 5′-acga
gcacaagctcacctct-3′; gDNA-hWPRE-reverse, 5′-tcagcaaac
acagtgcacacc-3′. gDNA PCR was normalized to beta-
actin: gDNA-hACTB-forward, 5′-ggagaatggcccagtcctc-3′;
and gDNA-hACTB-reverse, 5′-ggtctcaagtcagtgtacagg-3′
[20]. Total RNA was isolated using PSCs grown only on
feeder-free conditions to prevent MEF mRNA contamin-
ation issues with Roche’s High Pure RNA Isolation Kit in
accordance with the instructions of the manufacturer
(Roche, Indianapolis, IN, USA). Then 700 ng PSCs and
300 ng all fibroblast lines’ RNA were reverse-transcribed
using the Transcriptor First Strand cDNA Synthesis Kit,
using anchored-oligo(dT)18 and random hexamer primers
(Roche). PCR was performed using the KAPA HiFi
Hotstart ReadyMix PCR kit (KAPA) with a five-step PCR
protocol: initial denaturation at 95°C for 5 minutes; 28
cycles of each of the following: denaturation at 98°C for 20
seconds, primer annealing at 64°C for 15 seconds, and ex-
tension at 72°C for 15 seconds; followed by a single cycle
final extension at 72°C for 5 minutes. In total, 75 ng RNA
was used per reaction, and 12 μl with 3 μl loading dye was
loaded into a 3% agarose gel in accordance with the
recommendations of the manufacturer. Primers specific
to exon 4/5 splice junction analysis were: RT-hexon4/5-
forward, 5′-tgagcatgctgttctagctgcagga-3′; and RT-hexon4/
5-reverse, 5′-accaggaggaccatcatcaccac-3′. RT-PCR gene
expression was normalized to beta-actin: RT-hACTB-
forward, 5′-ggagaatggcccagtcctc-3′; and RT-hACTB-
reverse, 5′-ggtctcaagtcagtgtacagg-3′.Global transcriptional meta-analysis
Pre-excised and post-excised iPSCs were grown in stand-
ard feeder-free culture conditions as stated above and
harvested for total mRNA using a High Pure RNA Isola-
tion Kit in accordance with the instructions of the manu-
facturer (Roche). Microarray analysis was carried out as
published [35]. Affymetrix data adhered to the standards
proposed by the Functional Genomics Data Society and
were deposited in a MIAME-compliant format into the
Gene Expression Omnibus [36] [GEO:GSE48830]. Each
CEL file was uploaded to GeneSifter (VisX Labs, Seattle,
WA, USA) using the Advanced Upload Method and nor-
malized using the Affymetrix Microarray Analysis Suite
(MAS) 5.0 (Santa Clara, CA, USA) algorithm. GeneSifter
pairwise analysis between samples was performed using all
mean normalization and t-test statistical analysis (P <0.05).
For each pairwise analysis, two replicates from each cell line
were compared. Probe sets were considered significantly
different when P <0.05 and fold change ≥2.
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Total RNA was isolated using PSCs grown only on feeder-
free conditions to prevent MEF mRNA contamination is-
sues as stated above. Primers and probes were designed
and ordered from Roche’s Universal ProbeLibrary. Quanti-
tative PCR relative expression experiments used a
LightCycler 480 Real-Time PCR System (Roche), and
data were further analyzed with LightCycler 480 Soft-
ware release 1.5.0. Primers for the genes are listed as fol-
lows – primers specific for pre-loxP site analysis: QRT-h
PRPF39-forward, 5′-caggattttacaggctgggta-3′ and QRT-h
PRPF39-reverse, 5′-tcctggcagccatcaagt-3′, probe #2; QRT-
hPOU5F1-forward, 5′-gaagttaggtgggcagcttg-3′ and QRT-





probe #55; and gene expression was normalized using
HPRT1 and GAPDH primers: QRT-hHPRT1-forward,
5′-tgaccttgatttattttgcatacc-3′ and QRT-hHPRT1-reverse,
5′-cgagcaagacgttcagtcct-3′, probe #73; and QRT-GAPDH-
forward, 5′-gctctctgctcctcctgttc-3′ and QRT-GAPDH-
reverse, 5′-acgaccaaatccgttgactc-3′, probe #60. Five
nanograms per sample were used in a 20 μl reaction that
consisted of 10 μM UPL probe, 2× LightCycler 480 Probes
Master, and 20 μM forward and reverse primers. Triplicate
experimental samples were paired using the all-to-mean
pairing rule with two housekeeping genes run in duplicate
for advanced relative quantification.
Sequencing
Total RNA was extracted as stated above and amplified
with the hexon 4/5 primers and purified with a PCR
purification kit (Qiagen, Valencia, CA, USA). Samples
were sent for full-service sequencing at UCLA’s Genotyping
and Sequencing Core (Los Angeles, CA, USA) using
Invitrogen/Applied Biosystems 3730 Capillary DNA
Analyzers, and sequence results were analyzed on ApE
by (M. Wayne Davis; [37]).
Immunocytochemistry
Cultured cells were fixed in 4% paraformaldehyde/1×
PBS for 15 minutes, washed twice with 1× PBS
supplemented with 100 mM glycine for 5 minutes, and
then incubated, when needed, with permeabilization buf-
fer consisting of 0.1% Triton X-100 (Sigma-Aldrich) in
1× PBS for 30 minutes at room temperature. Blocking
was performed with 4% goat serum in Blocker Casein in
PBS (Thermo Scientific, Rockford, IL, USA) for 60 mi-
nutes at room temperature. The cells were then incubated
for 2.5 hours with primary antibody at room temperature.
Cells were washed with PBS after primary antibodystaining and following each subsequent step. Following
primary antibody incubation, the coverslips/wells were
incubated with Alexa Fluor secondary antibodies
(Invitrogen) at room temperature for 1 hour and mounted
in Prolong Gold with 4′,6-diamidino-2-phenylindole
(Invitrogen). Cultures were visualized with an AxioCam
MR Monocolor Camera and AxioVision Digital Image
Processing Software (Axio Observer Inverted Microscope;
Carl Zeiss, Jena, Germany).
The primary antibodies used for PSC characterization
are mouse anti-Oct-3/4 (C-10) (1:200; Santa Cruz Bio-
technology, Santa Cruz, CA, USA), rat anti-SSEA-3
(1:200; Millipore), mouse anti-SSEA-4 (1:200; Millipore),
mouse anti-TRA-1-60 (1:200; Millipore), mouse anti-
TRA-1-81 (1:200; Millipore), and rabbit anti-NANOG
(1:100; Abcam, Cambridge, MA, USA) [32]. For oligo-
dendrocyte progenitor and oligodendrocyte cells, the
following primary antibodies were used: mouse anti-
NG2 (1:25; eBioscience, San Diego, CA, USA), rabbit
anti-PDGFRα (1:20; Abcam), rabbit anti-SOX10 (1:20;
Abcam), mouse anti-OLIG1 (1:200; Millipore), mouse
anti-A2B5 (1:50; Millipore), mouse anti-O4 (1:40; R&D
Systems, Minneapolis, MN, USA), mouse anti-O1 (1:40;
R&D Systems), and rat anti-Myelin Basic Protein (1:40;
Abcam). To analyze oligodendrocyte and neuronal co-
culture, and to ensure oligodendrocyte human origin,
rabbit anti-TUJ-1 (1:2500; Covance, Inc., Emeryville,
CA, USA) and mouse anti-human mitochondria (1:40;
Millipore) antibodies were used, respectively. For hep-
atocyte cells, the following primary antibodies were
used: mouse anti-CK18 (1:50; Dako, Carpinteria, CA,
USA), mouse anti-serum albumin (1:50; R&D Systems),
and mouse anti-alpha-fetoprotein (1:100; Invitrogen).
For cardiomyocytes, the following primary antibodies
were used: mouse anti-Troponin I (1:50; Millipore) and
mouse anti-alpha-actinin (Sarcomeric) (1:100; Sigma-
Aldrich). For fibroblast differentiation, the following
primary antibody was used: mouse anti-COL3A1 (1:40;
Santa Cruz Biotechnology).
Induced pluripotent stem cell-directed differentiation
For oligodendrocyte progenitor and mature oligodendro-
cyte differentiation, embryoid bodies (EBs) were made on
day 1 by 1 mg/ml collagenase treatment for 10 minutes,
followed by gentle scraping with a 5-ml serological pipette.
Detached colonies were collected and transferred to low-
adhesion plates (Sigma-Aldrich) in a 50:50 combination of
mTeSR1 and Glial Restrictive Media and differentiated as
published [38]. For co-culture experiments, rat dorsal root
ganglion (DRG) neurons were dissected and cultured as
previously described, except for the substitution of rat
DRG neurons [39]. DRG neurons were cultured on
Matrigel (BD Biosciences) for a period of 7 days before
post-excised derived oligodendrocyte progenitor cells were
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cells/well in a 24-well plate. All cells were cultured in Glial
Restrictive Media. Co-cultured cells were cultured for a
period of 7 days before fixation and immunostaining.
For EB-directed beating cardiomyocyte differentiation,
post-excised iPSCs were incubated with 1 mg/ml colla-
genase for 10 minutes and then quenched with standard
differentiation media consisting of standard DMEM as
listed above but with 20% FBS and also with inclusion of
50 μg/ml ascorbic acid (Sigma-Aldrich), followed by
making strips of iPSCs with a 5-ml serological pipette
and subsequent placement into low-adhesion plates
(Sigma-Aldrich). Media were changed every day with
fresh media until day 5, when EBs were plated onto 0.2%
gelatin-coated plates. The FBS concentration was reduced
to 5% on day 10, and media were changed every 4 to 5
days with fresh ascorbic acid [40].
For non-EB-directed cardiomyocyte differentiation,
post-excised iPSCs cultured on Matrigel were changed
to DMEM/F-12 (Invitrogen) supplemented with 1× N2,
2 mM L-glutamine, 1 mM nonessential amino acid, 1×
B27 supplement (all from Invitrogen), 0.5 mg/ml bovine
serum albumin (Fraction V; Sigma-Aldrich), and 0.11 mM
2-mercaptoethanol (Millipore) (N2/B27-CDM) supple-
mented with 50 ng/ml recombinant human BMP-4 and
50 ng/ml recombinant human activin A (both from
PeproTech, Rocky Hill, NJ, USA) for 3 or 4 days and
cultured in N2/B27-CDM without additional factors for
an additional 8 to 10 days. The medium was changed
daily [41].
For hepatocyte differentiation, post-excised iPSCs were
grown on Matrigel as stated above until reaching a 60 to
70% confluence upon which endoderm induction was
initiated by replacing the post-excised iPSCs for 24 hours
with RPMI 1640 medium (Invitrogen/Gibco, Rockville,
MD, USA), supplemented with 0.5 mg/ml albumin frac-
tion V (Sigma-Aldrich), and 100 ng/ml Activin A
(PeproTech). On the following 2 days, 0.1 and 1% insu-
lin–transferrin–selenium (Invitrogen/Gibco) were added
to the medium, respectively. Post-excised iPSCs were
then cultured in hepatocyte culture medium (Lonza,
Walkersville, MD, USA) containing 30 ng/ml fibroblast
growth factor-4 and 20 ng/ml BMP2 (PeproTech) for 4
days. The now-differentiated cells were then incubated
in hepatocyte culture medium containing 20 ng/ml
hematopoietic growth factor and 20 ng/ml keratinocyte
growth factor (PeproTech) for 6 days, in hepatocyte cul-
ture medium containing 10 ng/ml oncostatin-M (R&D
Systems) plus 0.1 μM dexamethasone (Sigma-Aldrich)
for 5 days, and in DMEM containing N2, B27, 1×
Glutamax, 1× nonessential amino acid, and 1× β-
mercaptoethanol (all from Invitrogen/Gibco) for 3
more days. Media were changed daily during differenti-
ation [42].For fibroblast differentiation, EBs were cultured in
adherent conditions on 0.2% gelatin using standard
fibroblast media with 10% FBS and were passaged until
typical fibroblast morphology was seen [43].
Karyotype analysis
Post-excised iPSCs were passaged onto a 25-cm2 flask to
60 to 70% confluency and sent out for G-band karyotyping
analysis (Cell Line Genetics, Madison, WI, USA).
Teratoma formation
Teratomas for the pre-excised and post-excised iPSC lines
were generated by injecting 8 × 106 cells resuspended in
Hanks’ balanced salt solution (Invitrogen) into the two
testes in a severe combined immunodeficient adult male
beige mouse. All tumors were dissected 6 to 8 weeks after
injection and fixed in 4% formaldehyde, and sections
were paraffin-embedded and then stained with H & E
for further analysis at the UCLA Translational Pathology
Laboratory. All animal experiments were performed in
accordance with the UCLA Animal Research Committee
and the UCLA Division of Laboratory Animal Medicine.
Good manufacturing practice conversion and analysis
Post-excised iPSCs were slowly transitioned from
mTeSR1 media conditions to a 1:1 ratio of mTeSR1 and
NutriStem (Stemgent) and finally to a 1:1 ratio of
TeSR2/NutriStem (STEMCELL Technologies, Vancou-
ver, BC, Canada) supplemented with 1× Primocin
(InvivoGen) and 1× basic fibroblast growth factor
(GlobalStem), which are both defined xeno-free media
(containing no animal proteins). This conversion used
0:100, 20:80, 50:50, 80:20, and 100:0 mTeSR1/
NutriStem:TeSR2/NutriStem ratios, with each condition
lasting for 3 days. Regular passaging was maintained
every 4 or 5 days based on cell morphology and density.
Once cells were converted to the 1:1 TeSR2/NutriStem,
the cells were mechanically passaged with an 18-gauge
needle in the presence of 1× ROCK inhibitor (Stemgent),
preconditioned in the media for 1 hour, and then trans-
ferred to a xeno-free substrate (Synthemax; Sigma-
Aldrich). Cells were initially fibroblastic in nature, and
continual differentiation of the iPSCs had to be taken
out with a hand-pulled glass pipette. Specific selection of
proper iPSC colonies over a period of 2 or 3 weeks
generated morphologically homogeneous and standard-
looking iPSCs. Cells that were converted to xeno-free
conditions were then transferred to the UCLA good
manufacturing practice (GMP)-compatible facility and
underwent extended cultivation (for over 3 months) under
xeno-free conditions. The cells were then subjected to
standardized quality-control testing to ensure viability,
sterility, and appropriate cellular composition, which in-
cluded immunocytochemical analysis of stem cell markers,
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contaminants, including bacteria, fungi, mycoplasma or
sialic acid (Neu5Gc) contamination, and confirmation they
possessed a normal karyotype, and were cryobanked for
potential future clinical applications as previously de-
scribed [31]. To further show the broad applicability of
our slow transition methodology across media and
synthetic matrices, we also converted the post-excised
cells to a fully defined, synthetic matrix called CELLstart
(Invitrogen) and cultured in NutriStem media alone.
Flow cytometry-based detection of sialic acid
contamination
Flow cytometry was performed on the BD LSRII
flow cytometer and all data were analyzed with BD
FACSDiva Version 6.1.3 Software (BD Biosciences). The
cell surface expression of nonhuman sialic acid Neu5Gc
(N-glycolylneuraminic acid) was detected utilizing the
chicken anti-Neu5Gc IgG (1:200) (Sialix anti-Neu5Gc
Basic Pack Kit; Sialix San Diego, CA, USA) and labeled
with FITC-conjugated donkey anti-chicken IgG (H + L)
(1:200; Jackson ImmunoResearch, West Grove, PA,
USA). 4’,6-Diamidino-2-phenylindole (Invitrogen) was
included as previously published [35]. Standard condi-
tions and experimental controls were performed as per
manufacturer recommendations (Sialix). hiPSCs that
were derived and maintained under xeno-free clinical
grade conditions and mouse embryonic fibroblasts
(Globalstem) served as negative and positive controls,
respectively. Additionally, post-excised iPSCs in mTeSR1
plated on Matrigel and post-excised iPSCs in xeno-free
NutriStem plated on CELLstart were utilized for this
assay.
Statistical analysis
Results are presented as means ± standard deviations. The
statistical significance of differences for PRPF39 gene ex-
pression was evaluated using SPSS 20 (IBM Corporation,
Chicago, IL, USA). Analysis of variance, a t test for inde-
pendent samples, and Kruskal–Wallis nonparametrical
one-way analysis of variance tests were considered statisti-
cally significant with P <0.05.
Results
Induced pluripotent stem cell generation and
characterization
Previous work has shown that adult somatic human der-
mal fibroblasts can be efficiently reprogrammed into
iPSCs through exogenous expression of four transcrip-
tion factors (OCT4, KLF4, c-MYC, and SOX2) with a
single polycistronic lentivirus, or STEMCCA, flanked by
loxP sites (hSTEMCCA-loxP) [16]. We reprogrammed
low-passage adult human dermal fibroblasts through
transduction of hSTEMCCA. To induce reprogramming,1 × 105 fibroblasts were transduced with a constitutively
active hSTEMCCA-loxP. From these 100,000 cells, 60
colonies with ESC-like morphology were observed, pro-
viding a reprogramming efficiency of just over 0.05%, an
efficiency which parallels that seen in the literature
(Table 1). Twenty colonies were picked and iPSC lines
were derived. The 16 iPSC lines with the best morph-
ology were expanded and cryopreserved. Three iPSC
lines were thawed and expanded for further analysis for
this study. All three iPSC lines possessed typical human
ESC-like morphology, including large nucleoli, a high
nucleus-to-cytoplasm ratio, and tight compact colonies
(Figure 1A). All three iPSC lines, which we define here
as parental pre-excised C-3, C-8, and C-11, were origin-
ally cultured on MEF layers and standard ESC media
conditions for over 20 passages, representing the most
commonly used research-grade conditions for iPSC
derivation and culture.
Nonrestrictive linear amplification PCR genomic mapping
of integration into PRPF39 and pre-excised induced
pluripotent stem cell characterization
Third-generation lentiviruses are capable of integrating
into the host genome of primitive human repopulating
cells multiple times, initially seeming to limit the practical-
ity of using these viruses for reprogramming (for personal-
ized cellular therapeutics) and warranting the need for
new reprogramming methodologies that yield transduc-
tions with fewer copies per cell [44]. Optimization of the
multiplicity of infection to between 0.1 and 10, however,
recently demonstrated that over 94% of iPSC colonies had
a single stable integration [16]. Extensive and site-specific
genomic mapping to identify potential insertional muta-
genesis and elucidate adverse gene expression effects is
needed to establish therapeutically relevant and factor-free
iPSC lines. To verify a single integrated STEMCCA line
and specifically sequence and map the vector integration,
nrLAM-PCR was used to analyze the vector-human gen-
ome location. Two lines (C3 and C8) demonstrated single
intron-based integrations, and the third line (C11) demon-
strated multiple integrations. The C3 iPSC line displayed
one integration located in intron 5 of the lysosomal
enzyme alpha-N-acetylgalactosaminidase (NAGA), and
the C8 (pre-excised) iPSC line displayed one integration
located in intron 4 of pre-mRNA-processing factor
39 (PRPF39), a protein known to interact with the
spliceosome and play a role in pre-RNA processing [45].
Mutations in NAGA have been associated with Schindler
disease [46], whereas mutations in PRPF39 have not been
correlated with any specific disease. We therefore focused
our characterization and transcriptional analysis on the
C8 line.
The C8 pre-excised iPSC line expressed the pluripotency
markers alkaline phosphatase, NANOG, OCT4, SSEA-3,
Figure 1 Representative colonies from the three hSTEMCCA-derived induced pluripotent stem cell lines. (A) Only the C8 pre-excised
induced pluripotent stem cell (iPSC) line was found to have one integration into the PRPF39 gene and was therefore selected to undergo Adeno-
Cre-PuroR selection for removal of the cassette. (B) Excision of hSTEMCCA from the pre-excised iPSC adult parental line (C8). RT-PCR of genomic
DNA with primers against hSTEMCCA elements endo-Myc-s and A-WPRE, showing that one subclone (2.3 post-excised iPSCs) was free of the
integrated provirus. Bars = 100 μM.
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munocytochemistry (Figure 2A). Also, to demonstrate
pluripotency, iPSCs were injected into the testes of a se-
vere combined immunodeficient mouse. The pre-excised
iPSC line successfully formed teratomas representative of
all three germ layers: neural tube (ectoderm), gut epithe-
lium (endoderm), and cartilage (mesoderm) (Figure 2B).
These results demonstrate that our single integrated
hiPSC line is pluripotent and able to contribute to repre-
sentatives of all three germ layers.
Adeno-Cre-puro excision
We next sought to generate a factor-free line void of
any exogenous transgenic factors by expression of a
nonintegrating adenovirus expressing both Cre-
recombinase and puromycin resistance for selection
of post-excised iPSC colonies. C3 and C8 iPSC cells
were transduced for 24 hours with the Adeno-Cre-
PuroR adenovirus and exposed to puromycin for 5 days,
and then colonies were picked to establish three subclones
from each colony (C3 subclones 1.1, 1.2, and 1.3 and C8
subclones 2.1, 2.2, and 2.3) after 2 weeks of recovery
growth. We determined that successful Adeno-Cre-
mediated excision of hSTEMCCA-loxP reprogramming
construct occurred in only subclone 2.3, now called the
post-excised iPSC subcloned line, as determined through
PCR of genomic DNA with primers against endo-Myc-s
and A-WPRE (Figure 1B). Expanded post-excised iPSCs
were re-exposed to puromycin for 5 days, resulting in100% cell death of all subcloned colonies and demonstrat-
ing that the Adeno-Cre-PuroR did not integrate into the
genome following excision. Following Cre-mediated exci-
sion, post-excised iPSCs displayed a stable, uniform hu-
man ESC-like morphology for over 10 passages on MEFs
and maintained pluripotent markers (alkaline phosphatase,
NANOG, OCT4, SSEA-3, SSEA-4, TRA-1-60, and TRA-
1-81) at a level comparable with that of the pre-excised
iPSC line and control human ESCs (Figure 2A). Import-
antly, to avoid any MEF mRNA contamination issues in
later applications, both the pre-excised and post-excised
iPSC lines were transitioned into feeder-free conditions on
Matrigel with mTeSR1 media. Post-excised cells also were
able to maintain their pluripotency, as shown through
their successful contribution to all three germ layers in
teratoma formation (Figure 2B). Also, the post-excised
iPSC line was able to maintain genomic stability for over
37 passages during the transition from pre-excised to
post-excised hiPSCs as demonstrated by the normal
karyotype maintained (Figure 2C). The completely factor-
free post-excised iPSCs were therefore able to maintain
pluripotency markers and a normal karyotype and to
retain the ability to differentiate to representatives of all
three germ layers in the teratoma assay.
PRPF39 gene expression and splicing analysis
Successful excision of the hSTEMCCA-loxP site [16,47]
and specific loci mapping of the virus integration were
reported [31], but this study did not examine gene
Figure 2 Characterization of pre-excised and post-excised induced pluripotent stem cell lines. (A) Expression of pluripotency markers from
induced pluripotent stem cells (iPSCs) (human embryonic stem cells and parental fibroblasts from which the pre-excised iPSC line was derived
serving as controls), showing similar expression of all markers before and after hSTEMCCA excision. (B) Histological analysis of teratomas derived
from the pre-excised iPSC parental line and post-excised iPSC line. (C) G-band karyotyping analysis of the post-excised iPSC line, showing a
normal 46XY karyotype following excision of hSTEMCCA. Bars = 100 μM.
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line in detail with sensitive real-time RT-PCR. We there-
fore sought to investigate the differential gene expression
due to the lentiviral integration of hSTEMCCA-loxP
into the integrated gene (that is, PRPF39). Even after ex-
cision, approximately 200 base pairs of exogenous DNA
from the inactive long terminal repeat (LTR) remain in-
tegrated into the genome in intron 4 of PRPF39. This
finding emphasizes the importance of gene expression
analysis [48]. First, we performed microarray analysis on
the pre-excised and post-excised iPSCs, and like previ-
ous investigators [31] we found no statistically signifi-
cant difference between the gene expression for the
integrated gene (PRPF39) (data not shown). Next, we
used quantitative PCR to analyze the expression of
PRPF39 with exon-spanning primers across exons 2 and
3. The pre-excised iPSC line demonstrated a statistically
significant increase in the expression of PRPF39 com-
pared with the post-excised iPSC line and every other
cell line tested (Figure 3A). We confirmed this higher
expression by running three different fibroblast lines as
controls and showing very low expression of PRPF39 in
fibroblasts (Figure 3A). To investigate whether this
expression difference was due to random insertional
positional events in the genome, the multi-integration
line iPSCs that had three integrations were also ana-
lyzed, and they yielded a nonstatistically significant dif-
ference with the post-excised iPSC line of PRPF39 geneexpression. This suggests that the expression difference
of the pre-excised iPSC line is specifically due to the in-
sertion of the hSTEMCCA-loxP viral construct into the
PRPF39 intron 4 and that, following excision, endogen-
ous and homeostatic levels of PRPF39 gene resumes. To
further confirm correct splicing patterns, primers span-
ning exon 4 and 5 were used, and proper splicing was
confirmed throughout all of the lines tested, including
both pre-excised and post-excised iPSC lines (Figure 3B).
Also, to confirm the splicing product homogeneity and
proper PCR amplification, all lines tested were se-
quenced and yielded identical sequences. Importantly,
although aberrantly increased PRPF39 expression is seen
in the pre-excised iPSC line, the post-excised line was
able to revert back to normal levels of expression, indi-
cating that the leftover LTR region was being properly
removed during splicing.
Differentiation into clinically relevant cell types
To determine whether our transgene-free iPSC line was
capable of differentiating into therapeutically relevant
cell types, four different cell lineages were derived. First,
oligodendrocyte progenitor cells (which could prove useful
for treatment of spinal cord injuries) were differentiated
and shown to express characteristic oligodendrocyte pro-
genitor cell markers using immunocytochemistry. Oligo-
dendrocyte progenitors express A2B5, NG2, OLIG1,
SOX10, PDGFRα, and O4 (Figure 4A). After in vitro
Figure 3 Expression and splicing analysis of the pre-excised
and post-excised lines. (A) Quantitative PCR analysis showed that
integration into the PRPF39 gene caused a statistically significant
increase in transcript expression, in which the increased expression
was abrogated upon Adeno-Cre-PuroR-mediated hSTEMCCA
excision. No statistical differences were seen between all control
induced pluripotent stem cell (iPSC) lines, and all fibroblast lines
displayed very low expression of PRPF39, indicating that this gene is
associated with pluripotency. (B) To confirm that proper splicing of
the transcript is taking place, primers against exons 4 + 5 show that
no cryptic splice sites were being introduced and that, upon
excision, the transcript correctly spliced itself. P <0.05. ESC,
embryonic stem cell; Multiple Int., multiple integration; Syn.,
synthetic.
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indicating that we derived functionally mature oligoden-
drocytes (Figure 4B) [38]. However, it is well known that
in vitro maturation is inefficient and minimal myelin pro-
duction is produced without addition of further cytokines
[38,49]; thus oligodendrocyte progenitor cell maturation is
normally presented in vivo, where three-dimensional mye-
lination formation is easier to achieve [50]. Therefore, to
increase the efficiency of the in vitro model, the oligo-
dendrocyte progenitor cells were co-cultured with rat
DRG neurons to show an enhanced ability of the oligo-
dendrocytes to produce myelin and myelinate DRG axons;
human mitochondria were also stained to prove no con-
tamination of rat oligodendrocytes in the co-culture
(Figure 4C). This is an important step in developing an
in vitro co-culture system that can allow oligodendro-
cytes to wrap around axons and display myelination
capabilities. Second, functional hepatocytes were derived,
as indicated by positive staining for glycogen synthesis
following the periodic acid–Schiff test (which could proveuseful for treatment of liver diseases such as urea cycle
disorders). Cytokeratin 18, serum albumin, and alpha-
fetoprotein also were localized with these hepatocytes
(Figure 4D). Third, post-excised iPSCs were differentiated
into fibroblasts (which could prove useful to generate large
numbers of therapeutically useful autologous fibroblasts
following gene correction, such as for Epidermolysis
Bullosa) that stained positive for a characteristic fibroblast
marker, Col3A1 (Figure 4E, left image), at levels compar-
able with those of control fibroblasts (Figure 4E, right
image). Lastly, we derived cardiac myocytes [41] (which
could be useful for treatment of heart disease) that were
able to beat in culture [40] (see Additional file 1) and
also stain positively for alpha-actinin and troponin1
(Figure 4F). Post-excised iPSCs therefore not only
maintained pluripotency following hSTEMCCA-loxP exci-
sion and proper PRPF39 expression levels, but also were
able to differentiate into four functionally useful cell types
that have direct therapeutic applications.
Transition from research-grade to putative clinical-grade
induced pluripotent stem cells
We slowly transitioned our research-grade lines from a
xeno-containing substrate and media to xeno-free condi-
tions that maintained the pluripotent capability and func-
tionality of the hiPSCs. Transitioning of post-excised
iPSCs to xeno-free media conditions consisting of a 1:1
blend of NutriStem/TeSR2 was carried out over a period
of 30 days, and this was considered a slow conversion
methodology. After the post-excised iPSC line was stably
passaging in the xeno-free media, the cells were passaged
onto a xeno-free substrate called Synthemax and passaged
multiple times, and only the best colonies were selected
for each passage (Figure 5A). Next, we performed an
extended cultivation (for more than 3 months) of our
transgene-free iPSCs in defined xeno-free conditions (free
from nonhuman serum, proteins, and cells) under current
GMP manufacturing facilities (inspected and licensed by
the state of California) and used qualified defined reagents
and a standardized protocol [51]. The cells were also
subjected to standardized quality-control testing to ensure
viability, sterility, and appropriate cellular composition,
including expression of standard stem cell markers
(NANOG, OCT4, and SOX2) as indicated by quantitative
PCR analysis (Figure 5B). We also converted the post-
excised line from Matrigel and mTeSR1 to xeno-free and
chemically defined CELLstart and NutriStem media under
the same slow transition methodology as that used for the
Synthemax and mTeSR1/NutriStem conversion. We used
a different xeno-free substrate, and NutriStem alone, to
show the robustness of the methodology across substrates
and reagents. Both GMP grade conversions (Synthemax
and CELLstart) yielded comparable expression of standard
pluripotency markers (Figure 5B). Additionally, the pre-
Figure 4 Differentiation into therapeutically relevant cell lineages. (A) Post-excised induced pluripotent stem cells (iPSCs) were
differentiated into oligodendrocyte progenitor cells expressing characteristic progenitor stage markers. (B) Upon terminal differentiation, the
progenitor cells matured and displayed the mature antigen O1 and also stained positive for secreting myelin basic protein (MBP), a hallmark of
mature oligodendrocytes. (C) Due to low efficiency of in vitro oligodendrocyte maturation, a co-culture system with dorsal root ganglion neurons
was utilized and showed mature oligodendrocytes intimately associated with, and myelinating, neurite outgrowths. Additionally, human
mitochondria were stained to display that rat oligodendrocytes were not contaminating the culture. (D) Hepatocytes were derived that stained
positively for glycogen synthesis as indicated by the periodic acid–Schiff stain, and CK18, albumin, and alpha-fetoprotein. (E) Derived fibroblasts
stained positive for COL3A1 upon differentiation and at levels comparable with those of control fibroblasts (left picture is iPSC-derived fibroblasts
and right are control fibroblasts). (F) Cardiomyocytes showed expression of alpha-actinin and Troponin 1. DAPI, 4′,6-diamidino-2-phenylindole.
Bars = 50 μM.
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flow cytometry, for the sialic acid/N-glycolylneuraminic
acid (Neu5Gc), indicative of a nonhuman animal product
contamination [52]. The iPSC line, xHUF-1, which was
derived under completely defined and xeno-free condi-
tions, and MEFs, which are of mouse origin, were used to
show the negative and positive specificity of the antibody
towards Neu5Gc, respectively. As expected, the MEF cells
and the GMP iPSC line were 98.8% and 0% positive for
Neu5GC, respectively (Figure 5C). We found that the
post-excised line kept on Matrigel and in mTeSR1 media
still possessed significant Neu5Gc, detectable on 1% of
cells, but that this Neu5Gc was subsequently completely
lost during the GMP conversion process. We did not de-
fine whether this 1% Neu5Gc detection was attributed to
contaminating nonhuman epitopes from the original
MEFs, serum and/or Matrigel. Regardless, this Neu5Gc
detection approach is a stringent assay to determine iPSCs
and their derivatives are free from animal epitopes that
could lead to an immunogenic response [53].
Discussion
In this study, we show successful derivation of hiPSCs
from human adult somatic dermal fibroblasts that containa single hSTEMCCA-loxP lentiviral integration. We used
nrLAM-PCR technology to analyze both the number of
integrations in each line and the site in the genome where
the lentiviral provirus integrated. One pre-excised line
was derived with a single integration found to map into
intron 4 of PRPF39 (a gene not associated with any dis-
ease). Following Adeno-Cre-PuroR-mediated excision, a
factor-free line, termed post-excised iPSCs, was derived
and propagated.
Because previous studies using the polycistronic human
STEMCCA lentivirus did not analyze the expression and
splicing patterns of an integrated and subsequently excised
hSTEMCCA construct in detail, we sought to characterize
the expression and splicing patterns of our post-excised
iPSC line. Small inactive viral LTRs left in the genome are
thought to cause a small risk of insertional mutagenesis
[16]. A recent paper, however, argues that only transcrip-
tionally active LTRs, and not transcriptionally inactive
LTRs, are capable of forming myeloid tumors, even when
multiple LTR copies are present [54]. Previous studies also
showed that HIV-based vectors have a clear correlation
between increased gene activity hotspots and integration
site preference [28], although not specifically into tran-
scriptional start sites as seen with retroviruses [54].
Figure 5 Morphology of transgene-free induced pluripotent stem cells following conversion to clinical-grade conditions. (A) Conversion
of post-excised iPSCs from a xeno-containing substrate, Matrigel, to a xeno-free containing substrate, Synthemax, under current good
manufacturing practice (GMP) conditions. (B) Quantitative PCR for pluripotency associated genes displays that pre-converted and post-converted
induced pluripotent stem cells (iPSCs) retain normal expression levels across multiple synthetic substrates. (C) Beyond the standard GMP-grade
sterility testing, a flow cytometry-based assay for a nonhuman antigen, N-glycolylneuraminic acid, displayed that upon GMP-grade conversion all
sialic acid detection was eliminated (1% with post-excised cells on Matrigel down to 0% with post-excised cells in GMP conditions). An iPSC line
derived under GMP conditions and mouse embryonic fibroblasts (MEFs) were used as negative and positive controls, respectively. hESC, human
embryonic stem cell; hIPSC, human induced pluripotent stem cell; PE CELLstart, post-excised iPSC CELLstart; PE Synthemax, post-excised iPSC
Synthemax; PE Matrigel, post-excised Matrigel.
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active LTR is low, the possibility of integration into a tran-
scriptionally active location and gene is high, and
therefore target gene expression and splicing data on the
integration site are critical. Although we show abnormally
increased gene expression in the pre-excised iPSC line, the
gene expression levels were reduced to basal levels upon
excision, and the post-excised line maintained a normal
pluripotent stem cell phenotype. Fortunately, the post-
excised iPSC line had proper splicing of PRPF39 mRNA, al-
though this is probably due to the wild-type nonintegrated
allele properly expressing PRPF39. It is important to show
that the lentiviral integration does not cause dominant
negative interactions with the wild-type allele, allowing
normal expression. PRPF39 gene expression was thereforeincreased, probably due to an enhancer element like the
woodchuck post-transcriptional regulatory element coded
by the lentivirus causing a post-transcriptional increase in
gene expression [55]. If current safe-harbor criteria are
expanded to include intron-based reprogrammed cells
that have been characterized to demonstrate a normal
post-excision integrated gene expression profile, such as
the cells described in this study, this will increase the pro-
portion of generated iPSC lines being considered for
therapeutic applications and thereby increase the feasibil-
ity of iPSC-based therapeutics. We also demonstrated that
the post-excised iPSC line was able to differentiate into
multiple therapeutically important cell types, such as he-
patocytes, cardiomyocytes, and oligodendrocyte progeni-
tor cells [56].
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research-grade transgene-free hiPSCs into cells that
could be used in future clinical therapeutics (clinical
grade). This transition from research grade to clinical
grade was previously performed for human ESCs initially
derived in the presence of nonhuman serum, proteins,
and cells [57]. Geron converted their research-grade
ESCs to clinical-grade ESCs by extended cultivation of
their cells in defined xeno-free conditions free from
nonhuman serum, proteins, and cells under current
GMP manufacturing facilities. These facilities involve
clean-room suites that are inspected and licensed by the
state of California and use of qualified defined reagents
and a standardized protocol, followed by standardized
quality-control testing. In this study, we used the same
approach and converted our research-grade transgene-
free iPSCs into putative clinical-grade iPSCs. We discov-
ered that while a small percentage (1%) of the research-
grade cells still demonstrated detectible nonhuman sialic
acid (which may induce an immunogenic response if
these cells had been used for autologous cellular thera-
peutics [53]), the post-converted cells no longer demon-
strated any detectible sialic acid, suggesting that these
cells were now clean and could be used without risking
an immunogenic response. However, several caveats
must be kept in mind. First, the previous US Food and
Drug Administration-approved conversion of research-
grade human pluripotent stem cells to clinical-grade
cells involved ESCs, not iPSCs, and it is not guaranteed
that the same conversion criteria will apply for iPSCs.
Second, the US Food and Drug Administration approval
technically applied to one specific derivative (oligo-
dendrocyte precursor cells) derived from the converted
clinical-grade ESCs, and suggests that a separate US
Food and Drug Administration approval would be re-
quired for each iPSC-derived, differentiated therapeutic
product. How the US Food and Drug Administration
will ultimately judge the clinical applicability of these
iPSCs, their derivatives, and other future iPSC-based
therapeutics initially derived under research-grade xeno-
containing conditions remains to be determined.Conclusions
In summary, we have demonstrated the derivation of a
factor-free hiPSC line using a polycistronic human
STEMCCA reprogramming virus. nrLAM-PCR-based
genomic mapping showed that the line had a single inte-
gration into a relatively safe location in intron 4 of the
PRPF39 gene. We then demonstrated proper expression
levels following excision of the viral construct, correct
splicing patterns, differentiation of the post-excised
iPSCs into therapeutically relevant cell lineages, and
transition into putative clinical-grade conditions.Additional file
Additional file 1: Is a video file showing spontaneous differentiation
of transgene-free iPSCs into functional beating cardiomyocytes.
Abbreviations
DMEM: Dulbecco’s modified Eagle’s medium; DRG: Dorsal root ganglion;
EB: Embryoid body; ESC: Embryonic stem cell; FBS: Fetal bovine serum;
GMP: Good manufacturing practice; H & E: Hematoxylin and eosin;
hiPSC: Human induced pluripotent stem cell; iPSC: Induced pluripotent stem
cell; MEF: Mouse embryonic fibroblast; miRNA: MicroRNA;
nrLAM: Nonrestrictive linear amplification; PBS: Phosphate-buffered saline;
PCR: Polymerase chain reaction; PSC: Pluripotent stem cell; RT: Reverse
transcription; STEMCCA: Stem cell cassette.
Competing interests
JAB and AV-C receive research funding for Fibrocell Science, Inc. JAB is a
scientific consultant for Fibrocell Science, Inc. The remaining authors declare
that they have no competing interests.
Authors’ contributions
JAB and JPA designed the experiments and wrote the manuscript, JPA,
PCL, CR, AV-C, and SK performed the iPSC derivation and characterization
experiments. JPA, PCL, CR, JD-D and AC performed the iPSC analysis
experiments. MGM derived and analyzed the fibroblasts. PEP assisted with
the oligodendrocyte characterization assays and GSL assisted with the
hepatocyte characterization assays. ADP and ATC assisted with teratoma
formation assays and analysis. VS and RAR directed the initial
reprogramming efforts. SK, WEL, JAZ, DBK, ADP, ATC and JAB directed the
establishment of the UCLA GMP facilities permitting the conversion and
characterization of clinical-grade iPSCs. All authors contributed to the final
draft of manuscript.
Acknowledgements
The authors would like to thank Gustavo Mostoslavsky for providing us
with the STEMCCA polycistronic reprogramming vector and Katie
Ingraham for assisting us with the Oligodendrocyte Precursor Cells co-
cultures. This work is based on a research collaboration with Fibrocell
Science and the Clinical Investigations for Dermal Mesenchymally-Obtained
Derivatives Initiative to generate safe patient-specific cell-based
therapeutics. This work was supported by funding from the Eli and Edythe
Broad Center of Regenerative Medicine and Stem Cell Research at UCLA,
The Phelps Family Foundation, Fibrocell Science, Inc. and the UCLA CTSI
Scholar’s Award to JAB, P01GM081621 (NIH) to ADP, 1R01HD058047 (NIH)
to ATC, 1U01HL100397 (NHLBI) and TR3-05569 (CIRM) to RAR, P01
GM081621-01A1 (NIH) to JAZ, 5K08HD057555-05 and 1R01NS071076-03A1
(NIH) to GSL, and #RT2-01985 (CIRM) to MGM. All authors were funded by
the aforementioned funding bodies or performed work/analysis that did
not require extramural funding. None of the aforementioned funding
bodies had any role in the design, collection, analysis or interpretation of
data contained within this manuscript.
Author details
1Department of Molecular and Medical Pharmacology, 23–120 Center for
Health Sciences, University of California, Los Angeles (UCLA), 650 Charles E.
Young Drive South, Los Angeles, CA 90095, USA. 2Department of Obstetrics
and Gynecology, Institute for Stem Cell Biology & Regenerative Medicine,
Stanford University School of Medicine, Stanford University, 265 Campus
Drive, Stanford, Stanford, CA 94305, USA. 3Department of Microbiology,
Immunology and Molecular Genetics, 609 Charles E. Young Drive East, UCLA,
Los Angeles, CA 90095, USA. 4Eli and Edythe Broad Center of Regenerative
Medicine and Stem Cell Research, 615 Charles E Young Drive South, UCLA,
Los Angeles, CA 90095, USA. 5Department of Pediatrics, Division of
Gastroenterology and Nutrition, 10833 Le Conte Ave, UCLA, Los Angeles, CA
90095, USA. 6Department of Surgery, 200 UCLA Medical Plaza, UCLA, Los
Angeles, CA 90095, USA. 7Department of Integrative Biology and Physiology,
612 Charles E. Young Drive East, UCLA, Los Angeles, CA 90095, USA.
Received: 10 April 2013 Revised: 26 June 2013
Accepted: 17 July 2013 Published: 26 July 2013
Awe et al. Stem Cell Research & Therapy 2013, 4:87 Page 14 of 15
http://stemcellres.com/content/4/4/87References
1. Yu J, Vodyanik MA, Smuga-Otto K, Antosiewicz-Bourget J, Frane JL, Tian S,
Nie J, Jonsdottir GA, Ruotti V, Stewart R, Slukvin II, Thomson JA: Induced
pluripotent stem cell lines derived from human somatic cells. Science
2007, 318:1917–1920.
2. Byrne JA: Generation of isogenic pluripotent stem cells. Hum Mol Genet
2008, 17:R37–R41.
3. Byrne J: Nuclear reprogramming and the current challenges in
advancing personalized pluripotent stem cell-based therapies. Gene Ther
Regul 2013, 7:1230002.
4. Patel M, Yang S: Advances in reprogramming somatic cells to induced
pluripotent stem cells. Stem Cell Rev 2010, 6:367–380.
5. Shao L, Feng W, Sun Y, Bai H, Liu J, Currie C, Kim J, Gama R, Wang Z, Qian
Z, Liaw L, Wu WS: Generation of iPS cells using defined factors linked via
the self-cleaving 2A sequences in a single open reading frame. Cell Res
2009, 19:296–306.
6. Okita K, Ichisaka T, Yamanaka S: Generation of germline-competent
induced pluripotent stem cells. Nature 2007, 448:313–317.
7. Hacein-Bey-Abina S, Von Kalle C, Schmidt M, McCormack MP, Wulffraat N,
Leboulch P, Lim A, Osborne CS, Pawliuk R, Morillon E, Sorensen R, Forster A,
Fraser P, Cohen JI, de Saint BG, Alexander I, Wintergerst U, Frebourg T,
Aurias A, Stoppa-Lyonnet D, Romana S, Radford-Weiss I, Gross F, Valensi F,
Delabesse E, Macintyre E, Sigaux F, Soulier J, Leiva LE, Wissler M, et al:
LMO2-associated clonal T cell proliferation in two patients after gene
therapy for SCID-X1. Science 2003, 302:415–419.
8. Yu J, Hu K, Smuga-Otto K, Tian S, Stewart R, Slukvin II, Thomson JA: Human
induced pluripotent stem cells free of vector and transgene sequences.
Science 2009, 324:797–801.
9. Jia F, Wilson KD, Sun N, Gupta DM, Huang M, Li Z, Panetta NJ, Chen ZY,
Robbins RC, Kay MA, Longaker MT, Wu JC: A nonviral minicircle vector for
deriving human iPS cells. Nat Methods 2010, 7:197–199.
10. Anokye-Danso F, Trivedi CM, Juhr D, Gupta M, Cui Z, Tian Y, Zhang Y, Yang
W, Gruber PJ, Epstein JA, Morrisey EE: Highly efficient miRNA-mediated
reprogramming of mouse and human somatic cells to pluripotency.
Cell Stem Cell 2011, 8:376–388.
11. Miyoshi N, Ishii H, Nagano H, Haraguchi N, Dewi DL, Kano Y, Nishikawa S,
Tanemura M, Mimori K, Tanaka F, Saito T, Nishimura J, Takemasa I,
Mizushima T, Ikeda M, Yamamoto H, Sekimoto M, Doki Y, Mori M:
Reprogramming of mouse and human cells to pluripotency using
mature microRNAs. Cell Stem Cell 2011, 8:633–638.
12. Kim D, Kim CH, Moon JI, Chung YG, Chang MY, Han BS, Ko S, Yang E, Cha KY,
Lanza R, Kim KS: Generation of human induced pluripotent stem cells by
direct delivery of reprogramming proteins. Cell Stem Cell 2009, 4:472–476.
13. Fusaki N, Ban H, Nishiyama A, Saeki K, Hasegawa M: Efficient induction of
transgene-free human pluripotent stem cells using a vector based on
Sendai virus, an RNA virus that does not integrate into the host
genome. Proc Jpn Acad Ser B Phys Biol Sci 2009, 85:348–362.
14. Warren L, Manos PD, Ahfeldt T, Loh YH, Li H, Lau F, Ebina W, Mandal PK,
Smith ZD, Meissner A, Daley GQ, Brack AS, Collins JJ, Cowan C, Schlaeger
TM, Rossi DJ: Highly efficient reprogramming to pluripotency and
directed differentiation of human cells with synthetic modified mRNA.
Cell Stem Cell 2010, 7:618–630.
15. Sommer CA, Stadtfeld M, Murphy GJ, Hochedlinger K, Kotton DN,
Mostoslavsky G: Induced pluripotent stem cell generation using a single
lentiviral stem cell cassette. Stem Cells 2009, 27:543–549.
16. Somers A, Jean JC, Sommer CA, Omari A, Ford CC, Mills JA, Ying L, Sommer
AG, Jean JM, Smith BW, Lafyatis R, Demierre MF, Weiss DJ, French DL,
Gadue P, Murphy GJ, Mostoslavsky G, Kotton DN: Generation of transgene-
free lung disease-specific human induced pluripotent stem cells using a
single excisable lentiviral stem cell cassette. Stem Cells 2010,
28:1728–1740.
17. Gonzalez F, Boue S, Izpisua Belmonte JC: Methods for making induced
pluripotent stem cells: reprogramming a la carte. Nat Rev Genet 2011,
12:231–242.
18. Takahashi K, Tanabe K, Ohnuki M, Narita M, Ichisaka T, Tomoda K, Yamanaka
S: Induction of pluripotent stem cells from adult human fibroblasts by
defined factors. Cell 2007, 131:861–872.
19. Sommer CA, Mostoslavsky G: The evolving field of induced pluripotency:
recent progress and future challenges. J Cell Physiol 2013, 228:267–275.
20. Sommer CA, Sommer AG, Longmire TA, Christodoulou C, Thomas DD,
Gostissa M, Alt FW, Murphy GJ, Kotton DN, Mostoslavsky G: Excision ofreprogramming transgenes improves the differentiation potential of iPS
cells generated with a single excisable vector. Stem Cells 2010, 28:64–74.
21. Karumbayaram S, Lee P, Azghadi SF, Cooper AR, Patterson M, Kohn DB, Pyle
A, Clark A, Byrne J, Zack JA, Plath K, Lowry WE: From skin biopsy to
neurons through a pluripotent intermediate under good manufacturing
practice protocols. Stem Cells Transl Med 2012, 1:36–43.
22. Streckfuss-Bomeke K, Wolf F, Azizian A, Stauske M, Tiburcy M, Wagner S,
Hubscher D, Dressel R, Chen S, Jende J, Wulf G, Lorenz V, Schon MP, Maier
LS, Zimmermann WH, Hasenfuss G, Guan K: Comparative study of human-
induced pluripotent stem cells derived from bone marrow cells, hair
keratinocytes, and skin fibroblasts. Eur Heart J 2012, 12:12.
23. Loh YH, Hartung O, Li H, Guo C, Sahalie JM, Manos PD, Urbach A, Heffner
GC, Grskovic M, Vigneault F, Lensch MW, Park IH, Agarwal S, Church GM,
Collins JJ, Irion S, Daley GQ: Reprogramming of T cells from human
peripheral blood. Cell Stem Cell 2010, 7:15–19.
24. Camnasio S, Carri AD, Lombardo A, Grad I, Mariotti C, Castucci A, Rozell B,
Riso PL, Castiglioni V, Zuccato C, Rochon C, Takashima Y, Diaferia G, Biunno
I, Gellera C, Jaconi M, Smith A, Hovatta O, Naldini L, Di Donato S, Feki A,
Cattaneo E: The first reported generation of several induced pluripotent
stem cell lines from homozygous and heterozygous Huntington’s
disease patients demonstrates mutation related enhanced lysosomal
activity. Neurobiol Dis 2012, 46:41–51.
25. Zwi-Dantsis L, Huber I, Habib M, Winterstern A, Gepstein A, Arbel G,
Gepstein L: Derivation and cardiomyocyte differentiation of induced
pluripotent stem cells from heart failure patients. Eur Heart J 2012, 22:22.
26. Pessach IM, Ordovas-Montanes J, Zhang SY, Casanova JL, Giliani S, Gennery
AR, Al-Herz W, Manos PD, Schlaeger TM, Park IH, Rucci F, Agarwal S,
Mostoslavsky G, Daley GQ, Notarangelo LD: Induced pluripotent stem cells:
a novel frontier in the study of human primary immunodeficiencies.
J Allergy Clin Immunol 2011, 127:1400–1407. e4.
27. Petit I, Kesner NS, Karry R, Robicsek O, Aberdam E, Muller FJ, Aberdam D, Ben-
Shachar D: Induced pluripotent stem cells from hair follicles as a cellular
model for neurodevelopmental disorders. Stem Cell Res 2012, 8:134–140.
28. Schroder AR, Shinn P, Chen H, Berry C, Ecker JR, Bushman F: HIV-1
integration in the human genome favors active genes and local
hotspots. Cell 2002, 110:521–529.
29. Grund N, Maier P, Giordano FA, Appelt JU, Zucknick M, Li L, Wenz F, Zeller
WJ, Fruehauf S, Allgayer H, Laufs S: Analysis of self-inactivating lentiviral
vector integration sites and flanking gene expression in human
peripheral blood progenitor cells after alkylator chemotherapy.
Hum Gene Ther 2010, 21:943–956.
30. Papapetrou EP, Lee G, Malani N, Setty M, Riviere I, Tirunagari LM,
Kadota K, Roth SL, Giardina P, Viale A, Leslie C, Bushman FD, Studer L,
Sadelain M: Genomic safe harbors permit high beta-globin transgene
expression in thalassemia induced pluripotent stem cells.
Nat Biotechnol 2011, 29:73–78.
31. Karumbayaram S, Lee P, Azghadi SF, Cooper AR, Patterson M, Kohn DB, Pyle
A, Clark A, Byrne J, Zack JA: From skin biopsy to neurons through a
pluripotent intermediate under good manufacturing practice protocols.
Stem Cells Translational Med 2012, 1:36–43.
32. Byrne JA, Nguyen HN, Reijo Pera RA: Enhanced generation of induced
pluripotent stem cells from a subpopulation of human fibroblasts.
PLoS One 2009, 4:e7118.
33. Paruzynski A, Arens A, Gabriel R, Bartholomae CC, Scholz S, Wang W, Wolf S,
Glimm H, Schmidt M, von Kalle C: Genome-wide high-throughput
integrome analyses by nrLAM-PCR and next-generation sequencing.
Nat Protoc 2010, 5:1379–1395.
34. Langmead B, Trapnell C, Pop M, Salzberg SL: Ultrafast and memory-
efficient alignment of short DNA sequences to the human genome.
Genome Biol 2009, 10:R25.
35. Crespo AV, Awe JP, Pera RR, Byrne JA: Human skin cells that express
stage-specific embryonic antigen 3 associate with dermal tissue
regeneration. BioResearch Open Access 2012, 1:25–33.
36. Gene Expression Omnibus. www.ncbi.nlm.nih.gov/geo.
37. ApE. http://biologylabs.utah.edu/jorgensen/wayned/ape.
38. Izrael M, Zhang P, Kaufman R, Shinder V, Ella R, Amit M, Itskovitz-Eldor J,
Chebath J, Revel M: Human oligodendrocytes derived from embryonic
stem cells: effect of noggin on phenotypic differentiation in vitro and on
myelination in vivo. Mol Cell Neurosci 2007, 34:310–323.
39. Runyan SA, Phelps PE: Mouse olfactory ensheathing glia enhance axon
outgrowth on a myelin substrate in vitro. Exp Neurol 2009, 216:95–104.
Awe et al. Stem Cell Research & Therapy 2013, 4:87 Page 15 of 15
http://stemcellres.com/content/4/4/8740. Cao N, Liu Z, Chen Z, Wang J, Chen T, Zhao X, Ma Y, Qin L, Kang J, Wei B,
Wang L, Jin Y, Yang HT: Ascorbic acid enhances the cardiac
differentiation of induced pluripotent stem cells through promoting the
proliferation of cardiac progenitor cells. Cell Res 2012, 22:219–236.
41. Yao S, Chen S, Clark J, Hao E, Beattie GM, Hayek A, Ding S: Long-term self-
renewal and directed differentiation of human embryonic stem cells in
chemically defined conditions. Proc Natl Acad Sci U S A 2006, 103:6907–6912.
42. Song Z, Cai J, Liu Y, Zhao D, Yong J, Duo S, Song X, Guo Y, Zhao Y, Qin H,
Yin X, Wu C, Che J, Lu S, Ding M, Deng H: Efficient generation of
hepatocyte-like cells from human induced pluripotent stem cells. Cell Res
2009, 19:1233–1242.
43. Patterson M, Chan DN, Ha I, Case D, Cui Y, Van Handel B, Mikkola HK, Lowry
WE: Defining the nature of human pluripotent stem cell progeny. Cell Res
2012, 22:178–193.
44. Woods NB, Muessig A, Schmidt M, Flygare J, Olsson K, Salmon P, Trono D,
von Kalle C, Karlsson S: Lentiviral vector transduction of NOD/SCID
repopulating cells results in multiple vector integrations per transduced
cell: risk of insertional mutagenesis. Blood 2003, 101:1284–1289.
45. Stark AL, Delaney SM, Wheeler HE, Im HK, Dolan ME: Functional
consequences of PRPF39 on distant genes and cisplatin sensitivity.
Hum Mol Genet 2012, 17:17.
46. Wang AM, Schindler D, Desnick R: Schindler disease: the molecular lesion
in the alpha-N-acetylgalactosaminidase gene that causes an infantile
neuroaxonal dystrophy. J Clin Invest 1990, 86:1752–1756.
47. Soldner F, Hockemeyer D, Beard C, Gao Q, Bell GW, Cook EG, Hargus G,
Blak A, Cooper O, Mitalipova M, Isacson O, Jaenisch R: Parkinson’s disease
patient-derived induced pluripotent stem cells free of viral
reprogramming factors. Cell 2009, 136:964–977.
48. Sommer CA, Mostoslavsky G: Experimental approaches for the generation
of induced pluripotent stem cells. Stem Cell Res Ther 2010, 1:26.
49. Hu BY, Du ZW, Zhang SC: Differentiation of human oligodendrocytes
from pluripotent stem cells. Nat Protoc 2009, 4:1614–1622.
50. Nistor GI, Totoiu MO, Haque N, Carpenter MK, Keirstead HS: Human
embryonic stem cells differentiate into oligodendrocytes in high purity
and myelinate after spinal cord transplantation. Glia 2005, 49:385–396.
51. Karumbayaram S, Lee P, Azghadi SF, Cooper AR, Patterson M, Kohn DB, Pyle
A, Clark A, Byrne J, Zack JA, Plath K, Lowry WE: From skin biopsy to
neurons through a pluripotent intermediate under good manufacturing
practice protocols. Stem Cells Trans Med 2012, 1:36–43.
52. Diaz SL, Padler-Karavani V, Ghaderi D, Hurtado-Ziola N, Yu H, Chen X, der
Linden EC B-V, Varki A, Varki NM: Sensitive and specific detection of the
non-human sialic Acid N-glycolylneuraminic acid in human tissues and
biotherapeutic products. PLoS One 2009, 4:e4241.
53. Martin MJ, Muotri A, Gage F, Varki A: Human embryonic stem cells express
an immunogenic nonhuman sialic acid. Nat Med 2005, 11:228–232.
54. Montini E, Cesana D, Schmidt M, Sanvito F, Ponzoni M, Bartholomae C, Sergi
Sergi L, Benedicenti F, Ambrosi A, Di Serio C, Doglioni C, von Kalle C,
Naldini L: Hematopoietic stem cell gene transfer in a tumor-prone mouse
model uncovers low genotoxicity of lentiviral vector integration.
Nat Biotechnol 2006, 24:687–696.
55. Mastroyiannopoulos NP, Feldman ML, Uney JB, Mahadevan MS, Phylactou
LA: Woodchuck post-transcriptional element induces nuclear export of
myotonic dystrophy 3′ untranslated region transcripts. EMBO Rep 2005,
6:458–463.
56. Erceg S, Ronaghi M, Oria M, Rosello MG, Arago MA, Lopez MG, Radojevic I,
Moreno-Manzano V, Rodriguez-Jimenez FJ, Bhattacharya SS, Cordoba J,
Stojkovic M: Transplanted oligodendrocytes and motoneuron progenitors
generated from human embryonic stem cells promote locomotor
recovery after spinal cord transection. Stem Cells 2010, 28:1541–1549.
57. Geron Receives FDA Clearance to begin World’s First Human Clinical Trial of
Embryonic Stem Cell-based Therapy. http://ir.geron.com/phoenix.zhtml?
c=67323&p=irol-newsArticle&ID=1636192&highlight.
doi:10.1186/scrt246
Cite this article as: Awe et al.: Generation and characterization of
transgene-free human induced pluripotent stem cells and conversion to
putative clinical-grade status. Stem Cell Research & Therapy 2013 4:87.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
